Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
SanBio Co ( (JP:4592) ) just unveiled an update.
SanBio has released its financial results for the fiscal year ending January 31, 2026, along with forecasts for the current fiscal year, underscoring its ongoing commitment to regenerative medicine. The company also highlighted its strategic goal of leveraging Japan as its core base while pursuing global leadership in the field, signaling continued efforts to build operational scale and enhance its position in the regenerative medicine market.
The most recent analyst rating on (JP:4592) stock is a Sell with a Yen1794.00 price target. To see the full list of analyst forecasts on SanBio Co stock, see the JP:4592 Stock Forecast page.
More about SanBio Co
SanBio Company Ltd., listed on the TSE Growth Market under code 4592, operates in the regenerative medicine and biotechnology sector. The company focuses on developing advanced cell-based therapies with the ambition of positioning Japan as its strategic home base while expanding its presence as a global leader in regenerative medicine.
Average Trading Volume: 1,308,085
Technical Sentiment Signal: Sell
Current Market Cap: Yen138.3B
Learn more about 4592 stock on TipRanks’ Stock Analysis page.